Meldonium
(Mildronate) Research
The Latvian cardiac drug that rewired Soviet athletics — and caught 99 athletes in a single month. A carnitine inhibitor that forces your cells to burn glucose instead of fat, producing more energy per oxygen molecule under hypoxic stress.
📋 On this page
How Meldonium Works
Meldonium is a structural analogue of γ-butyrobetaine (GBB) — the natural precursor to L-carnitine. By mimicking GBB, it blocks the final enzyme in carnitine biosynthesis and forces a fundamental shift in cellular energy metabolism.
Why this matters under stress: During intense exercise, cardiac ischemia, or high-altitude conditions, oxygen delivery lags demand. Switching to glucose oxidation means the same amount of oxygen produces more ATP — potentially the difference between cardiac function and failure, or sustained performance and collapse.
What the Research Shows
Meldonium has an unusually robust clinical trial base for an Eastern European pharmaceutical, with approvals in over 10 countries and evidence across cardiovascular, cerebrovascular, and neurological indications.
99 Athletes, One Month
When WADA added meldonium to its banned list on January 1, 2016, it triggered the largest single-drug doping scandal in sports history. The drug had been openly used by Eastern European athletes for decades — treating it as nothing more than a standard cardiovascular supplement.
Dosing Protocols
Clinical dosing from Eastern European prescribing guidelines. These are not medical recommendations — meldonium is not approved for use in the US, EU, UK, Canada, or Australia.
- 500–1000mg/day orally (angina, CHF)
- Typical: 500mg twice daily
- Course length: 4–6 weeks, 2–3 courses/year
- Acute ischemia: up to 2g IV in clinical settings
- IV route: faster onset, 10% solution (5mL = 500mg)
- Post-MI rehabilitation: standard oral protocol
- Acute stroke: 500–1000mg IV daily × 10–14 days
- Then transition to 500mg twice daily oral
- Chronic cerebrovascular disease: 500mg 2×/day
- Cognitive support: 4–6 week oral courses
- Best studied in ischemic, not healthy populations
- Neuroprotection mechanism: Akt/GSK-3β pathway
- 500–1000mg/day orally, morning dose
- Cycle: 4–6 weeks on, 2 weeks off minimum
- Soviet military use at altitude: 500mg/day
- Half-life ~3–6 hours — morning dosing standard
- Fat-soluble? No — oral bioavailability ~78%
- ⚠️ WADA BANNED — not for competitive athletes
- Oral bioavailability: ~78%
- Tmax: ~1–2 hours post oral dose
- Half-life: 3–6 hours (short)
- Protein binding: low
- Elimination: primarily renal
- Detection window: weeks to months in urine (controversial)
Cycling rationale: Continuous use is not recommended because the body adapts by upregulating carnitine synthesis over time and efficacy diminishes. Periodic depletion/recovery cycles maintain the metabolic effect. Long-term continuous use in animal models has shown gut microbiome disruption.
Legal status: WADA Banned (S4) Rx — Eastern Europe Not FDA Approved Research Chemical (US)
Side Effects & Risk Assessment
Clinical safety data from Eastern European trials is generally favorable at therapeutic doses. Long-term safety in healthy users (non-cardiac populations) is not well-characterized.
Drug Interactions: L-Carnitine supplementation directly competes with meldonium for OCTN2 transport, accelerating elimination and reducing meldonium's effect — relevant both for washout strategies and assessing whether carnitine co-supplementation is useful. Combining with nitrates or antihypertensives may potentiate hypotensive effects due to additive NO/vasodilatory action.
Contraindications: Severe renal impairment (primarily renally cleared). Pregnancy and lactation (insufficient data). Hypersensitivity to the compound.
Legal Status by Country
Meldonium's legal status reflects its unusual position — approved medicine in some countries, banned doping substance in sport worldwide, and unregulated gray-market compound elsewhere.
| Country / Region | Status | Notes |
|---|---|---|
| Latvia | Approved (OTC) | Home of Grindeks, the manufacturer. Fully approved, available over-the-counter. |
| Russia | Approved (Rx) | Widely prescribed cardiovascular drug. Prescription required but broadly available. |
| Ukraine, Belarus, Kazakhstan, Georgia + CIS | Approved | Approved in most post-Soviet states as standard cardiovascular therapy. |
| United States | Not FDA Approved | Not scheduled/controlled. Not available through licensed US pharmacies. Available via gray-market suppliers. |
| European Union (exc. Latvia) | Not EMA Approved | No EU-wide approval. Not in EU formularies. Available through gray-market channels in some countries. |
| United Kingdom, Canada, Australia | Not Licensed | Not approved by regulatory authorities. Personal import rules vary. |
| WADA / All Sports | Banned (S4) | Prohibited in-competition AND out-of-competition. No established TUE pathway. 100 ng/mL reporting threshold. |
What We Know vs. What We Don't
Honest assessment of the evidence base — because distinguishing established science from speculation matters.
- Meldonium effectively inhibits carnitine synthesis — the biochemistry is well-established with crystallographic confirmation
- Forces a shift to glucose metabolism — confirmed in vivo by hyperpolarized MRI studies (Savic et al., 2021)
- Cardioprotective during ischemia — multiple RCTs in CHF and angina show improved exercise tolerance and cardiac function
- Reduces acylcarnitine accumulation during ischemia — confirmed in animal and human studies
- Approved medicine in 10+ countries for 40+ years with a generally clean safety profile at therapeutic doses
- GBB accumulation increases NO production and has independent cardioprotective properties
- Neuroprotective in acute stroke models and cerebrovascular disease patients
- Performance enhancement in healthy athletes — plausible mechanism but no robust RCTs in healthy subjects (Schobersberger et al., 2017)
- Long-term safety in non-cardiac populations — most trials 4–12 weeks; decades-long carnitine depletion effects unknown
- Optimal cycling protocol — the 4–6 week cycles are empirical, not scientifically optimized
- Interaction with modern cardiac medications — effects with statins, SGLT2 inhibitors, GLP-1 agonists unstudied
- Urine detection window — individual variation in clearance time was the central WADA controversy
- Benefits in healthy individuals vs. those with impaired cardiovascular/cerebrovascular function (selection bias in all trials)
Key Study Citations
Primary research behind the data on this page. Click PMID links to read full papers on PubMed.
🛒 Recommended Supplements
Relevant products for meldonium protocols and mitochondrial support. Affiliate links help support HighPeptides at no extra cost to you.
Amazon affiliate links — we earn a small commission at no extra cost to you. Product recommendations are based on relevance to this topic, not paid placement.
Explore Related Research
Other compounds in the nootropic, metabolic, and Soviet-era performance research space.
Want the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
Get the Guide →